Patents by Inventor Lars Uttenthal

Lars Uttenthal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnostic Test to Exclude Significant Renal Injury
    Publication number: 20190170770
    Abstract: Methods for determining the risk of developing acute renal failure in a human subject by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Inventors: Lars Uttenthal, Kristian Bangert
  • Diagnostic Test to Exclude Significant Renal Injury
    Publication number: 20100210031
    Abstract: Methods for determining the risk of developing acute renal failure in a human subject by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided.
    Type: Application
    Filed: August 3, 2007
    Publication date: August 19, 2010
    Applicant: AntibodyShop A/S
    Inventors: Lars Uttenthal, Kristian Bangert
  • Methods for Treating Local Tracheal, Bronchial or Alveolar Bleeding or Hemoptysis
    Publication number: 20070258971
    Abstract: The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of thrombotic agents to a subject via intratracheal, intrabronchial or intraalveolar administration of a blood coagulation factor to the subject.
    Type: Application
    Filed: September 9, 2005
    Publication date: November 8, 2007
    Applicant: PHARMAORGIN APS
    Inventors: Lars Heslet, Lars Uttenthal
  • Methods for preventing and treating local tracheal, bronchial or alveolar bleeding or hemoptysis
    Publication number: 20070060517
    Abstract: The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of thrombotic agents to a subject via intratracheal, intrabronchial or intraalveolar administration of a blood coagulation factor to the subject. Methods of the present invention are useful in treating diffuse alveolar hemorrhage secondary to blast lung injury, HIV infection and AIDS.
    Type: Application
    Filed: May 26, 2006
    Publication date: March 15, 2007
    Inventors: Lars Heslet, Lars Uttenthal